The PHLPP2 phosphatase is a druggable driver of prostate cancer progression

Nowak, D. G., Katsenelson, K. C., Watrud, K. E., Chen, M., Mathew, G., D'Andrea, V. D., Lee, M. F., Swamynathan, M. M., Casanova-Salas, I., Jibilian, M. C., Buckholtz, C. L., Ambrico, A. J., Pan, C. H., Wilkinson, J. E., Newton, A. C., Trotman, L. C. (May 2019) The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. J Cell Biol, 218 (6). pp. 1943-1957. ISSN 0021-9525

2019.Nowack.PHLPP2.pdf - Published Version

Download (3MB) | Preview
DOI: 10.1083/jcb.201902048


Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP53 tumor suppressor genes. In contrast, however, most candidate tumor suppressors are part of large recurrent hemizygous deletions, such as the common chromosome 16q deletion, which involves the AKT-suppressing phosphatase PHLPP2. Using RapidCaP, a genetically engineered mouse model of Pten/Trp53 mutant metastatic prostate cancer, we found that complete loss of Phlpp2 paradoxically blocks prostate tumor growth and disease progression. Surprisingly, we find that Phlpp2 is essential for supporting Myc, a key driver of lethal prostate cancer. Phlpp2 dephosphorylates threonine-58 of Myc, which renders it a limiting positive regulator of Myc stability. Furthermore, we show that small-molecule inhibitors of PHLPP2 can suppress MYC and kill PTEN mutant cells. Our findings reveal that the frequent hemizygous deletions on chromosome 16q present a druggable vulnerability for targeting MYC protein through PHLPP2 phosphatase inhibitors.

Item Type: Paper
Subjects: bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > genes, structure and function > genes: types > Myc
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein expression > phosphorylation
diseases & disorders > cancer > cancer types > prostate cancer
CSHL Authors:
Communities: CSHL labs > Trotman lab
CSHL Cancer Center Program > Cellular Communication in Cancer Program
Depositing User: Matthew Dunn
Date: 15 May 2019
Date Deposited: 29 May 2019 18:19
Last Modified: 29 Jun 2021 20:02
PMCID: PMC6548123
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving